All In Biotech

Drug Trial Radar · NCT01004185

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis

A Randomized, Double-blind, Parallel-group Study to Assess the Safety and Efficacy of Asacol® (1.2 to 4.8g/Day) 400 mg Delayed-release Tablets Given Twice Daily for 26 Weeks to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: May 25, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

39

Actual

Start

Oct 2009

Primary completion

Mar 2011

Study completion Mar 2011

Sponsor

Lead sponsor
Warner ChilcottIndustry
Sponsor type
Industry
First posted
Oct 29, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 5 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether low dose Asacol® (27 mg/kg - 71 mg/kg) and high dose Asacol® (53 mg/kg - 118 mg/kg) are safe and effective when dosed as 400 mg delayed-release tablets given twice daily for 26 weeks to children and adolescents for the maintenance of remission of ulcerative colitis.

Conditions

  • Ulcerative Colitis

Interventions

  • Asacol 400 mgDrug

    17-33kg = 3 Asacol 400mg AM \& 2 Asacol 400mg PM; 33-\<54kg = 5 Asacol 400 mg AM \& 4 Asacol 400mg PM; 54-\<90kg = 6 Asacol 400mg AM \& PM

  • Asacol 400 mgDrug

    17-\<33kg = 2 Asacol 400mg \& 1 placebo AM, 1 Asacol 400mg \& 1 placebo PM; 33-\<54kg = 3 Asacol 400mg \& 2 placebo AM, 2 Asacol 400mg \& 2 placebo PM; 54-\<90kg = 3 Asacol 400mg \& 3 placebo AM \& PM

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Success PUCAI (Pediatric Ulcerative Colitis Activity Index), mITT/Modified Intent to Treat PopulationTime frame: Week 26

Locations

51 sites in 6 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Loma Linda, California

  • Research Site

    San Diego, California

  • Research Site

    San Francisco, California

  • Research Site

    San Francisco, California

  • Research Site

    Gainesville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Park Ridge, Illinois

  • Research Site

    Louisville, Kentucky

  • Research Site

    Portland, Maine

  • Research Site

    Boston, Massachusetts

  • Research Site

    Worcester, Massachusetts

  • Research Site

    Southfield, Michigan

  • Research Site

    Jackson, Mississippi

  • Research Site

    Kansas City, Missouri

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Mays Landing, New Jersey

  • Research Site

    Buffalo, New York

  • Research Site

    New Hyde Park, New York

  • Research Site

    Providence, Rhode Island

  • Research Site

    Nashville, Tennessee

  • Research Site

    Fort Worth, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Huntington, West Virginia

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Halifax, Nova Scotia, Canada

  • Research Site

    Hamilton, Ontario, Canada

  • Research Site

    London, Ontario, Canada

  • Research Site

    Ottawa, Ontario, Canada

  • Research Site

    Rijeka, Croatia

  • Research Site

    Zagreb, Croatia

  • Research Site

    Bialystok, Poland

  • Research Site

    Bydgoszcz, Poland

  • Research Site

    Katowice, Poland

  • Research Site

    Krakow, Poland

  • Research Site

    Lodz, Poland

  • Research Site

    Warsaw, Poland

  • Research Site

    Wroclaw, Poland

  • Research Site

    Bucharest, Romania

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.